An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding

References

• Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs. 2010;2:347–11. doi:https://doi.org/10.4161/mabs.2.3.11779.
   PubMed Web of Science ®Google Scholar
• Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93:1390–402. doi:https://doi.org/10.1002/jps.20079.
   PubMed Web of Science ®Google Scholar
• Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm Sci. 2011;100:5081–95. doi:https://doi.org/10.1002/jps.22705.
   PubMed Web of Science ®Google Scholar
• Vazquez E, Corchero JL, Villaverde A. Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact. 2011;10:60. doi:https://doi.org/10.1186/1475-2859-10-60.
   PubMed Web of Science ®Google Scholar
• Skamris T, Tian X, Thorolfsson M, Karkov HS, Rasmussen HB, Langkilde AE, Vestergaard B. Monoclonal antibodies follow distinct aggregation pathways during production-relevant acidic incubation and neutralization. Pharm Res. 2016;33:716–28. doi:https://doi.org/10.1007/s11095-015-1821-0.
   PubMed Web of Science ®Google Scholar
• Richard J, Prang N. The formulation and immunogenicity of therapeutic proteins: product quality as a key factor. IDrugs. 2010;13:550–58.
   PubMedGoogle Scholar
• Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100:354–87. doi:https://doi.org/10.1002/jps.22276.
   PubMed Web of Science ®Google Scholar
• Majumdar R, Esfandiary R, Bishop SM, Samra HS, Middaugh CR, Volkin DB, Weis DD. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. mAbs. 2015;7:84–95. doi:https://doi.org/10.4161/19420862.2014.985494.
   PubMed Web of Science ®Google Scholar
• Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. Aaps J. 2006;8:E572–9. doi:https://doi.org/10.1208/aapsj080366.
   PubMed Web of Science ®Google Scholar
• Obrezanova O, Arnell A, de la Cuesta RG, Berthelot ME, Gallagher TR, Zurdo J, Stallwood Y. Aggregation risk prediction for antibodies and its application to biotherapeutic development. mAbs. 2015;7:352–63. doi:https://doi.org/10.1080/19420862.2015.1007828.
   PubMed Web of Science ®Google Scholar
• Ho SC, Wang T, Song Z, Yang Y. IgG aggregation mechanism for CHO cell lines expressing excess heavy chains. Mol Biotechnol. 2015;57:625–34. doi:https://doi.org/10.1007/s12033-015-9852-7.
   PubMed Web of Science ®Google Scholar
• Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille J-F, Viaud-Massuard M-C, Diot P, Si-Tahar M, Vecellio L, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. mAbs. 2014;6:1347–55. doi:https://doi.org/10.4161/mabs.29938.
   PubMed Web of Science ®Google Scholar
• Jung S, Honegger A, Pluckthun A. Selection for improved protein stability by phage display . J Mol Biol. 1999;294:163–80. doi:https://doi.org/10.1006/jmbi.1999.3196.
   PubMed Web of Science ®Google Scholar
• Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. 2004;22:1161–65. doi:https://doi.org/10.1038/nbt1000.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106:11937–42. doi:https://doi.org/10.1073/pnas.0904191106.
   PubMed Web of Science ®Google Scholar
• Latypov RF, Hogan S, Lau H, Gadgil H, Liu D. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem. 2012;287:1381–96. doi:https://doi.org/10.1074/jbc.M111.297697.
   PubMed Web of Science ®Google Scholar
• Gong R, Wang Y, Ying T, Feng Y, Streaker E, Prabakaran P, Dimitrov DS. N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance. Mol Pharm. 2013;10:2642–52. doi:https://doi.org/10.1021/mp400075f.
   PubMedGoogle Scholar
• Yageta S, Lauer TM, Trout BL, Honda S. Conformational and colloidal stabilities of isolated constant domains of human immunoglobulin G and their impact on antibody aggregation under acidic conditions. Mol Pharm. 2015;12:1443–55. doi:https://doi.org/10.1021/mp500759p.
   PubMedGoogle Scholar
• Chen W, Kong L, Connelly S, Dendle JM, Liu Y, Wilson IA, Powers ET, Kelly JW, et al. Stabilizing the CH2 domain of an antibody by engineering in an enhanced aromatic sequon. ACS Chem Biol. 2016;11:1852–61. doi:https://doi.org/10.1021/acschembio.5b01035.
   PubMed Web of Science ®Google Scholar
• Zeng F, Yang C, Gao X, Li X, Zhang Z, Gong R. Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment. J Biol Chem. 2018;293:19127–35. doi:https://doi.org/10.1074/jbc.RA118.005367.
   PubMed Web of Science ®Google Scholar
• Gao X, Conard A, Yang C, Zhan Y, Zeng F, Shi J, Li W, Dimitrov DS, Gong R. Optimization of the C-terminus of an autonomous human IgG1 CH2 domain for stability and aggregation resistance. Mol Pharm. 2019;16:3647–56. doi:https://doi.org/10.1021/acs.molpharmaceut.9b00544.
   PubMedGoogle Scholar
• Schaefer JV, Pluckthun A. Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression. J Mol Biol. 2012;417:309–35. doi:https://doi.org/10.1016/j.jmb.2012.01.027.
   PubMed Web of Science ®Google Scholar
• Courtois F, Agrawal NJ, Lauer TM, Trout BL. Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. mAbs. 2016;8:99–112. doi:https://doi.org/10.1080/19420862.2015.1112477.
   PubMed Web of Science ®Google Scholar
• Perchiacca JM, Tessier PM. Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng. 2012;3:263–86. doi:https://doi.org/10.1146/annurev-chembioeng-062011-081052.
   PubMed Web of Science ®Google Scholar
• Lee CC, Perchiacca JM, Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol. 2013;31:612–20. doi:https://doi.org/10.1016/j.tibtech.2013.07.002.
   PubMed Web of Science ®Google Scholar
• Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall’Acqua W, Minter R, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. mAbs. 2013;5:255–62. doi:https://doi.org/10.4161/mabs.23392.
   PubMed Web of Science ®Google Scholar
• Chakroun N, Hilton D, Ahmad SS, Platt GW, Dalby PA. Mapping the aggregation kinetics of a therapeutic antibody fragment. Mol Pharm. 2016;13:307–19. doi:https://doi.org/10.1021/acs.molpharmaceut.5b00387.
   PubMedGoogle Scholar
• Chen X, Zeng F, Huang T, Cheng L, Liu H, Gong R. Optimization on Fc for improvement of stability and aggregation resistance. Curr Pharm Biotechnol. 2016;17:1353–59. doi:https://doi.org/10.2174/1389201017666161117145312.
   PubMed Web of Science ®Google Scholar
• Yang C, Gao X, Gong R. Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-Based therapeutics. Front Immunol. 2017;8:1860. doi:https://doi.org/10.3389/fimmu.2017.01860.
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Engineered CH2 domains (nanoantibodies). mAbs. 2009;1:26–28. doi:https://doi.org/10.4161/mabs.1.1.7480.
   PubMed Web of Science ®Google Scholar
• Ying T, Gong R, Ju TW, Prabakaran P, Dimitrov DS. Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta. 2014;1844:1977–82. doi:https://doi.org/10.1016/j.bbapap.2014.04.018.
   PubMed Web of Science ®Google Scholar
• Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, Dimitrov D. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. Curr Drug Discov Technol. 2014;11:28–40. doi:https://doi.org/10.2174/15701638113109990032.
   PubMedGoogle Scholar
• Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, et al. Engineered human antibody constant domains with increased stability. J Biol Chem. 2009;284:14203–10. doi:https://doi.org/10.1074/jbc.M900769200.
   PubMed Web of Science ®Google Scholar
• Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor. J Biol Chem. 2011;286:27288–93. doi:https://doi.org/10.1074/jbc.M111.254219.
   PubMed Web of Science ®Google Scholar
• Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun. 2009;387:387–92. doi:https://doi.org/10.1016/j.bbrc.2009.07.044.
   PubMed Web of Science ®Google Scholar
• Li D, Gong R, Zheng J, Chen X, Dimitrov DS, Zhao Q. Engineered antibody CH2 domains binding to nucleolin: isolation, characterization and improvement of aggregation. Biochem Biophys Res Commun. 2017;485:446–53. doi:https://doi.org/10.1016/j.bbrc.2017.02.058.
   PubMed Web of Science ®Google Scholar
• Linding R, Schymkowitz J, Rousseau F, Diella F, Serrano L. A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. J Mol Biol. 2004;342:345–53. doi:https://doi.org/10.1016/j.jmb.2004.06.088.
   PubMed Web of Science ®Google Scholar
• Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004;22:1302–06. doi:https://doi.org/10.1038/nbt1012.
   PubMed Web of Science ®Google Scholar
• Rousseau F, Schymkowitz J, Serrano L. Protein aggregation and amyloidosis: confusion of the kinds? Curr Opin Struct Biol. 2006;16:118–26. doi:https://doi.org/10.1016/j.sbi.2006.01.011.
   PubMed Web of Science ®Google Scholar
• Gong R, Wang Y, Ying T, Dimitrov DS. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS One. 2012;7:e42288. doi:https://doi.org/10.1371/journal.pone.0042288.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Vu BK, Gan J, Feng Y, Dimitrov DS, Ji X. Structure of an isolated unglycosylated antibody C(H)2 domain. Acta Crystallogr Sect D Biol Crystallogr. 2008;64:1062–67. doi:https://doi.org/10.1107/S0907444908025274.
   PubMed Web of Science ®Google Scholar
• Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A. 1969;63:78–85. doi:https://doi.org/10.1073/pnas.63.1.78.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293:1155–59. doi:https://doi.org/10.1126/science.1061692.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol. 2009;391:404–13. doi:https://doi.org/10.1016/j.jmb.2009.06.028.
   PubMed Web of Science ®Google Scholar
• Sahin E, Jordan JL, Spatara ML, Naranjo A, Costanzo JA, Weiss WF, Robinson AS, Fernandez EJ, Roberts CJ, et al. Computational design and biophysical characterization of aggregation-resistant point mutations for gammaD crystallin illustrate a balance of conformational stability and intrinsic aggregation propensity. Biochemistry. 2011;50:628–39. doi:https://doi.org/10.1021/bi100978r.
   PubMed Web of Science ®Google Scholar